TAThomas Peter Almdal

Thomas Peter Almdal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Peter Almdal has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiac arrhythmia and hypoglycaemia among individuals with and without diabetes receiving haemodialysis (the CADDY study): a Danish multicentre cohort study

    by Dea H. Kofod, Søren Z. Diederichsen, Tobias Bomholt, Mads Ø. Andersen, Andreas Andersen, Ebba Mannheimer, Marianne Rix, Ylian S. Liem, Kristine Lindhard, Henrik P. Hansen, et al.

    Aims/hypothesis: We aimed to examine arrhythmias and hypoglycaemia among individuals with and without diabetes who are receiving haemodialysis and to investigate the association between arrhythmias and hypoglycaemia, hyperglycaemia and glycaemic variability. Methods: This prospective multicentre cohort study included 70 participants on maintenance haemodialysis (35 with diabetes and 35 without diabetes). We employed implantable cardiac monitors for continuous heart rhythm monitoring in combination with periodic use of continuous glucose monitoring. Logistic-regression-type linear mixed models were used to examine associations between arrhythmias and glycaemic measures. Results: During 18 months of follow-up, clinically significant arrhythmias (bradyarrhythmia and ventricular tachycardia) were identified in 12 (34%) participants with diabetes and 11 (31%) without diabetes. Atrial fibrillation was detected in 13 (37%) participants with diabetes and 14 (40%) without, while other supraventricular tachycardia was detected in seven (20%) and 11 (31%) participants with and without diabetes, respectively. Hypoglycaemia (sensor glucose 10.0 mmol/l) was associated with a decreased rate of arrhythmias among participants with diabetes (IRR 0.58 [95% CI 0.37, 0.92]). Glycaemic variability showed no association with arrhythmias regardless of the presence of diabetes. Conclusions/interpretation: Arrhythmias and hypoglycaemia were common in those undergoing haemodialysis regardless of diabetes status. Our data suggest a temporal relationship between arrhythmias and glucose level in both individuals with and without diabetes. Trial registration: Clinicaltrials.gov: NCT04841304. Graphical


  • Open Access

    Effect and acceptability of co-created interventions linking public rehabilitation programs with civil society involvement for physical activity engagement – a convergent mixed methods pilot study

    by Ida Kær Thorsen, Julie Midtgaard, Marie Lønberg Hansen, Katja Thomsen, Henrik Søborg, Helle Oldrup Jensen, Thomas Peter Almdal, Janne Kunchel Lorenzen, Anders Blædel Gottlieb Hansen, Mathias Ried-Larsen

    Background: Public physical activity programs are time-limited and often lacking sufficient support for citizens to maintain physical activity engagement. In this project, municipal stakeholders; civil society organizations; citizens with type 2 diabetes (T2D), cardiovascular diseases (CVD), and/or obesity; and researchers were involved in the co-creation and implementation of interventions to support citizens in continuing physical activity engagement following a municipal rehabilitation program. The primary aim of this study was to investigate the effect of these interventions on physical activity engagement in civil society sports organizations. Secondary aims were to investigate acceptability and effect of these interventions on physical and mental health, and organizational development and collaboration. Methods: This was a convergent mixed methods study using a quantitative prospective intervention study with a historic control group, and a qualitative descriptive study. These were analyzed separately and then integrated. Quantitative data from citizens were collected before; and 0, 3 and 6 months after ending their rehabilitation program. Outcomes included physical activity engagement in civil society organizations; and changes in objectively measured physical activity, physical and mental health. Qualitative data were collected among citizens, civil society, and municipal representatives. Themes included physical activity engagement, acceptability, and organizational development and collaboration. Results: Among the 33 included citizens (58% women, median (25 th ; 75 th percentile) age of 67.6 (63.9; 74.1) years), six lived with T2D; nine with CVD; and 18 were obese. Of the 21 citizens who were not engaged in physical activities in civil society organizations before entering the rehabilitation program, 67% started and remained active at 6-month follow-up—significantly more than in the historic control group. Light physical activity increased by a mean (95% confidence interval) of 15.4 (2.3; 28.5) min/day from 0 to 6 months after the rehabilitation program; all other outcomes remained unchanged. This was assisted by experienced high acceptability of the linking interventions and strengthened collaboration between the municipal health center and civil society organizations. Conclusions: The co-created interventions led to increased physical activity engagement in civil society organizations. This supports co-creation as a method to link municipal rehabilitation programs with physical activities in civil society organizations. Trial registration: ClinicalTrials.gov: NCT05493345 , 2022-08-05


  • Open Access

    Adding Different Exercise Training Volumes to a Diet-Induced Weight Loss Facilitates Fat Loss and Maintains Fat-Free Mass in a Dose-Depending Fashion in Persons with Newly Diagnosed Type 2 Diabetes: Secondary Findings from the DOSE-EX Multi-Arm, Parallel-Group, Randomized Trial

    by Mark P.P. Lyngbæk, Grit Elster Legaard, Nina Sloth Nielsen, Cody Garrett Durrer, Thomas Peter Almdal, Morten Asp Vonsild Lund, Benedikte Liebetrau, Caroline Ewertsen, Carsten Lauridsen, Thomas P.J. Solomon, et al.

    OBJECTIVE: To assess the dose-response effects of exercise in combination with a diet-induced weight loss on fat mass (FM) percentage (FM%) in persons with diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS: In this secondary analysis of a four-armed randomized trial ( Clinicaltrials.gov NCT03769883 ) 82 persons (35% females, mean age and standard deviation (SD) 58.2 (9.8) years) living with type 2 diabetes were randomly allocated to the control group (N=21, CON), diet control (25% energy restriction; N =20, DCON), diet control and exercise three times/week (two sessions of aerobic and one session combining resistance and aerobic training; N =20, MED), or diet control and exercise six times/week (four sessions of aerobic and two sessions combining resistance and aerobic training; N =21, HED) for 16 weeks. The primary outcome was the change in FM percentage points (pp). Secondary outcomes included fat-free mass and visceral adipose tissue volume. RESULTS: Type 2 diabetes duration was 4.0 years (interquartile range 1.9 to 5.5), body weight (SD) 101.4 kg (14.6), FM% (SD) 39.4 (6.7). FMpp decreased compared to standard care −3.5 pp (95% CI −5.6 to −1.4) p=0.002, −6.3 pp (CI −8.4 to −4.1) p<0.001, and −8.0 pp (95% CI −10.2 to −5.8) p<0.001, for DCON, MED, and HED, respectively. The difference between HED and MED was −1.8 pp [95% CI −3.9 to 0.4]; p=0.11). CONCLUSIONS: All interventions were superior in reducing FMpp compared to standard care in a dose-dependent manner. Adding three or six sessions of exercise to a low-calorie diet was superior in reducing FM compared to a low-calorie diet alone. Article Highlights: Why did we undertake this study? Exercise and weight loss are recommended for persons with type 2 diabetes. It is unclear if adding exercise, and which amount of exercise, to a low-calorie diet supports additional fat mass loss. What is the specific question(s) we wanted to answer? What is the dose-response effect of exercise combined with a moderate caloric restriction on changes in fat mass? What did we find? Adding exercise to a diet-induced weight loss reduced fat mass and preserved fat-free mass in a dose-dependent manner. What are the implications of our findings? Adding exercise to a moderate caloric restriction dose-dependently facilitates reductions in fat mass by enlarging weight loss and fat loss.


  • Open Access

    Effects of different doses of exercise and diet-induced weight loss on beta-cell function in type 2 diabetes (DOSE-EX): a randomized clinical trial

    by Grit E. Legaard, Mark P. P. Lyngbæk, Thomas P. Almdal, Kristian Karstoft, Sebastian L. Bennetsen, Camilla S. Feineis, Nina S. Nielsen, Cody G. Durrer, Benedikte Liebetrau, Ulrikke Nystrup, et al.

    Diet-induced weight loss is associated with improved beta-cell function in people with type 2 diabetes (T2D) with remaining secretory capacity. It is unknown if adding exercise to diet-induced weight loss improves beta-cell function and if exercise volume is important for improving beta-cell function in this context. Here, we carried out a four-armed randomized trial with a total of 82 persons (35% females, mean age (s.d.) of 58.2 years (9.8)) with newly diagnosed T2D ( 0.001 for trend). We report three serious adverse events (two in the control group and one in the diet control group), as well as adverse events in two participants in the diet control group, and five participants each in the moderate and high exercise dose groups. Overall, adding an exercise intervention to diet-induced weight loss improves glucose-stimulated beta-cell function in people with newly diagnosed T2D in an exercise dose-dependent manner (NCT03769883).


  • Open Access

    Oral capsules of tetra‐hydro‐cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment

    by Kanita Zubcevic, Merete Petersen, Flemming Winther Bach, Aksel Heinesen, Thomas Peter Enggaard, Thomas Peter Almdal, Jakob Vormstrup Holbech, Lene Vase, Troels Stahelin Jensen, Christian Stevns Hansen, et al.

    Background: Cannabinoids are often prescribed for neuropathic pain, but the evidence‐based recommendation is ‘weak against’.Objectives: The aim was to examine the effect of two cannabinoids and their combination in peripheral neuropathic pain.Methods: This was a randomized, double‐blind, trial with treatment arms for cannabidiol (CBD), tetra‐hydro‐cannabinol (THC), CBD and THC combination (CBD/THC), and placebo in a 1:1:1:1 ratio and flexible drug doses (CBD 5–50 mg, THC 2.5–25 mg, and CBD/THC 5 mg/2.5 mg–50 mg/25 mg). Treatment periods of 8‐week duration were proceeded by 1 week for baseline observations. Patients with painful polyneuropathy, post‐herpetic neuralgia and peripheral nerve injury (traumatic or surgical) failing at least one previous evidence‐based pharmacological treatment were eligible for inclusion. The primary outcome was the change in weekly average of daily pain measured with a numeric rating scale (NRS). Trail Making Test (TMT) was used as one of the tests of mental functioning.Results: In all, 145 patients were included in the study of which 118 were randomized and 115 included in the intention‐to‐treat analysis. None of the treatments reduced pain compared to placebo (p = 0.04–0.60). Effect sizes as estimated in week 8 (positive values worse and negative better than placebo) were CBD mean 1.14 NRS points (95% CI 0.11–2.19), THC 0.38 (CI −0.65 to 1.4) and CBD/THC −0.12 (−1.13 to 0.89).Conclusions: CBD, THC and their combination did not relieve peripheral neuropathic pain in patients failing at least one previous evidence‐based treatment for neuropathic pain.


  • Open Access

    Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study

    by Magnus T. Jensen, Peter Sogaard, Ida Gustafsson, Jan Bech, Thomas F. Hansen, Thomas Almdal, Simone Theilade, Tor Biering-Sørensen, Peter G. Jørgensen, Søren Galatius, et al.

    Cardiovascular disease is the most common comorbidity in type 1 diabetes. However, current guidelines do not include routine assessment of myocardial function. We investigated whether echocardiography provides incremental prognostic information in individuals with type 1 diabetes without known heart disease.


  • The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial

    by A. K. Nordklint, T. P. Almdal, P. Vestergaard, L. Lundby-Christensen, T. W. Boesgaard, L. Breum, B. Gade-Rasmussen, S. B. Sneppen, C. Gluud, B. Hemmingsen, et al.

    Some antihyperglycemic medications have been found to affect bone metabolism. We assessed the long-term effects of metformin compared with placebo on bone mineral density (BMD) and trabecular bone score (TBS) in patients with type 2 diabetes. Metformin had no significant effect on BMD in the spine and hip or TBS compared with a placebo.


  • Increased glucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjects after Roux-en-Y gastric bypass

    by S.G. Vienberg, S.H. Jacobsen, D. Worm, L.E. Hvolris, L. Naver, T. Almdal, D.L. Hansen, B.S. Wulff, T.R. Clausen, S. Madsbad, et al.

    Objective The positive metabolic outcome of Roux‐en‐Y gastric bypass (RYGB) surgery may involve fibroblast growth factor 21 (FGF21), in both the fasting state and postprandially. We measured the fasting levels of FGF21 before and after bariatric surgery as well as the postprandial FGF21 responses after a glucose load and after a mixed meal. Design Observational intervention trial. Patients and measurements Eight obese, nondiabetic patients underwent RYGB. Plasma FGF21 was measured both before and after surgery on three different days during oral glucose loads (25 g or 50 g glucose) or a mixed meal. Blood samples were taken right before the meal and at 15‐min intervals until 90 min and at 150 min and 210 min relative to the start of the meal. Results Overall, fasting plasma FGF21 did not change significantly before and after surgery (262 ± 71 vs 411 ± 119 pg/ml), but for three subjects, fasting plasma FGF21 increased significantly after surgery. Furthermore, FGF21 levels increased significantly at t = 90 and t = 150 min in response to 50 g glucose, but not after a mixed meal. Conclusions In conclusion, the observed increase in postprandial plasma FGF21 in response to glucose and the lack of FGF21 response to a mixed meal may have important implications for the physiologic role of FGF21. The increase in postprandial FGF21 in response to glucose in the early postoperative period may contribute to the metabolic improvements observed after gastric bypass.


  • Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer

    by Thor Chalmer, Thomas P Almdal, Tina Vilsbøll, Filip K Knop

    The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide , is a widely used drug for the treatment of type 2 diabetes. Liraglutide is one of several incretin-based agents that have been suggested to be associated with pancreatitis and pancreas cancer. The suspicion accelerated after publication of an autopsy study claiming increased incidences of several pathological changes in pancreata from patients with diabetes treated with incretin-based drugs. The aim of the present review is to give an overview of the pharmacology of liraglutide and provide a review of adverse reactions associated with liraglutide with a focus on the risk of pancreatitis and pancreas cancer. When comprehensively reviewing the available literature, no clear and significant associations between liraglutide and pancreatitis and/or pancreas cancer seem evident. However, a recently published analysis suggests a trend toward a slightly elevated risk of pancreatitis with GLP-1 receptor agonists (including liraglutide), which may become statistical significant as more data become available. Well-established side effects are of gastrointestinal origin, typical mild-to-moderate and of transient character. The risk of hypoglycemia associated with liraglutide treatment is low.


  • Open Access

    Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials

    by Pernille Kähler, Berit Grevstad, Thomas Almdal, Christian Gluud, Jørn Wetterslev, Allan Vaag, Bianca Hemmingsen

    Objectives Demographic and presentation profile of patients using an innovative mobile outreach clinic compared with mainstream practice. Design Retrospective cohort study. Setting Primary care mobile street health clinic and mainstream practice in Western Australia. Participants 2587 street health and 4583 mainstream patients. Main outcome measures Prevalence and patterns of chronic diseases in anatomical domains across the entire age spectrum of patients and disease severity burden using Cumulative Illness Rating Scale (CIRS). Results Multimorbidity (2+ CIRS domains) prevalence was significantly higher in the street health cohort (46.3%, 1199/2587) than age–sex-adjusted mainstream estimate (43.1%, 2000/4583), p=0.011. Multimorbidity prevalence was significantly higher in street health patients Conclusions Age–sex-adjusted multimorbidity prevalence and disease severity is higher in the street health cohort. Earlier onset (23–34 years) multimorbidity is found in the street health cohort but prevalence is lower in 65+ years than in mainstream patients. Multimorbidity prevalence is higher for Aboriginal patients of all ages.